The Wall Street Journal is looking past the FDA’s official ending of the GLP-1 shortages and into...
POLITICO Pro Q&A: Scott Brunner on Protecting Patient Access to Compounded GLP-1s
APC CEO Scott Brunner takes the spotlight in a new POLITICO Pro Q&A, highlighting the critical role compounding pharmacies play in ensuring patients get access to life-changing GLP-1 therapies. His message is clear: compounding is about patient care first, last, and always.
“Compounding pharmacies have stepped up and provided millions of patients access to what is undeniably a wonder drug at a time when the drugmakers could not meet the demand, and at a price point that the patient could afford, and with a track record of safety that is not out of sync with what we're seeing with the FDA-approved drug.”
Filling Gaps the Manufacturers Can’t
Scott reminded readers that compounding has never been about competing with drugmakers — it’s about stepping up when patients would otherwise go without.
“APC's position is that compounding should not be competition for FDA-approved drugs. It's a secondary therapy designed to fill gaps in drug supply that FDA-approved drugs can't fill.”
That commitment to patients has been on full display with GLP-1s, where prescribers have called for individualized formulations — sometimes dozens of variations — to meet unique patient needs.
Putting Patients First
In the interview, Scott pushed back on calls for heavier-handed regulation, making it clear that APC’s focus is protecting prescriber judgment and patient access.
“I would say FDA but certainly prescribers and compounding pharmacies are preferencing patient access to a wonder drug over the intellectual property rights of the drugmakers. These drugs, whether compounded or FDA-approved, are life-enhancing for millions of Americans, so I would argue that patient access is the better priority for this time that we're in.”
That’s the voice we’re proud to share on behalf of APC members: confident, clear, and unapologetically focused on patients.
Read the Full Interview
The full Q&A dives into the future of compounded GLP-1s, how the end of shortages affects the market, and why APC continues to fight for patient-first policies.
